Free Fatty Acid Compositions for Viral ARDS and Lung Inflammation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing treatments for acute respiratory distress syndrome (ARDS) caused by viral and bacterial respiratory infections, as well as other conditions, are inadequate in reducing fluid buildup in the lungs and associated inflammation, leading to oxygen deficiency and tissue damage.

Innovation Solution

Administration of fatty acid compositions, including derivatives and combinations, to mobilize free fatty acids from depot fat, thereby increasing serum fatty acid levels and reducing inflammatory cytokine production, which helps in inducing hypoxia tolerance and preventing viral binding to host cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing treatments are used for ARDS, then standard care is provided, but fluid buildup in lungs and inflammation are not adequately reduced

Engineering Contradiction:
Improveeffectiveness of treatmentVSAvoidfluid buildup and inflammation
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the biochemical parameters of the patient's system by administering fatty acid compositions that alter serum fatty acid levels, cytokine production, and metabolic state, thereby resolving the contradiction between standard care and inadequate reduction of fluid buildup and inflammation

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

Fatty acids serve as intermediary substances that mediate between the administered composition and the pathological processes, acting through multiple mechanisms including direct antiviral effects, anti-inflammatory actions, and induction of protective metabolic states to reduce harmful fluid buildup

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If fatty acid compositions are administered to increase serum fatty acid levels, then hypoxia tolerance and protection against viral binding are enhanced, but treatment complexity increases

Engineering Contradiction:
Improveprotection against ARDS and viral infectionsVSAvoidtreatment protocol
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The fatty acid composition serves multiple functions simultaneously: it prevents viral binding to host cells, reduces inflammatory cytokine production, induces hypoxia tolerance, and mobilizes energy reserves, thereby providing comprehensive protection through a single multi-functional intervention that offsets treatment complexity

Inventive Principle:
Principle #6Universality (Multi-functionality)

Data Source

PatentUS12440464B2Method for treating respiratory viral infections comprising administration of fatty acid compositions
Publication Date: 2025.10.14 IRAZU BIO

AI summary

Methods and compositions comprising free fatty acids for the treatment, including prevention, of viral infections, including the treatment of Acute Respiratory Distress Syndrome (ARDS). The compositions comprising free fatty acids, optionally linolenic acid, linoleic acid, and/or palmitic acid, may be used in methods for treating viral infections, optionally, coronavirus infections, for example, SARS-CoV, MERS-CoV, and/or SARS-CoV-2/COVID-19, and influenza virus infections, optionally, H1N1 and/or H5N1.